EUROFINS CEREP Inactive Instrument
Eurofins Cerep Share Price Euronext Paris
Equities
FR0012045946
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - EUR | - |
|
| 2023 | Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| 2022 | Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2022 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2021 | 4.16Cr 4.52Cr 376.65Cr | Sales 2022 | 4.76Cr 5.17Cr 431.06Cr | Capitalization | 11Cr 12Cr 1.01TCr |
|---|---|---|---|---|---|
| Net income 2021 | 90L 97.74L 81Cr | Net income 2022 | 1.1Cr 1.19Cr 100Cr | EV / Sales 2021 | 2.05 x |
| Net cash position 2021 | 12.82L 13.92L 12Cr | Net cash position 2022 | 1.28Cr 1.39Cr 115.88Cr | EV / Sales 2022 | 2.08 x |
| P/E ratio 2021 * |
-
| P/E ratio 2022 |
-
| Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 4.22% |
More Fundamentals
* Assessed data
More news
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 19/18/19 | |
Damien Séroux
CHM | Chairman | - | 13/14/13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Damien Séroux
CHM | Chairman | - | 13/14/13 |
| Director/Board Member | 68 | 10/15/10 | |
| Chief Executive Officer | - | 19/18/19 |
Eurofins Cerep (formerly Eurofins-Cerep) specializes in the pre-clinical research of drugs for the pharmaceutical industry.
Exports account for 97.9% of net sales.
Calendar
23/05/2024
- Shareholders Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +41.79% | 5.4TCr | |
| -0.56% | 4.19TCr | |
| +49.62% | 4.2TCr | |
| -7.20% | 2.84TCr | |
| +12.59% | 2.64TCr | |
| -21.51% | 1.9TCr | |
| +6.92% | 1.3TCr | |
| +24.91% | 1.22TCr | |
| +29.60% | 1.23TCr |
